- Stocks
- Healthcare
- NASDAQ: CRNX

Price (delayed)

$54.83

Market cap

$4.32B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.76

Enterprise value

$3.98B

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate,

CRNX's equity has surged by 62% since the previous quarter

The quick ratio has soared by 54% YoY and by 37% QoQ

CRNX's gross profit has plunged by 54% YoY and by 51% from the previous quarter

The revenue has dropped by 54% year-on-year and by 51% since the previous quarter

What are the main financial stats of CRNX

Market
Valuations
Earnings

Shares outstanding

78.86M

Market cap

$4.32B

Enterprise value

$3.98B

Price to earnings (P/E)

N/A

Price to book (P/B)

4.36

Price to sales (P/S)

2,007.91

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

2,015.78

Revenue

$1.97M

EBIT

-$235.46M

EBITDA

-$232.29M

Free cash flow

-$184.45M

Per share
Balance sheet
Liquidity

EPS

-$3.76

Free cash flow per share

-$2.55

Book value per share

$12.57

Revenue per share

$0.03

TBVPS

$13.53

Total assets

$978.15M

Total liabilities

$103.22M

Debt

$52.5M

Equity

$874.93M

Working capital

$865.46M

Debt to equity

0.06

Current ratio

17.72

Quick ratio

17.43

Net debt/EBITDA

1.48

Margins
Efficiency
Dividend

EBITDA margin

-11,767.5%

Gross margin

100%

Net margin

-11,928.3%

Operating margin

-12,571.4%

Return on assets

-37%

Return on equity

-42.5%

Return on invested capital

-49.6%

Return on capital employed

-25.4%

Return on sales

-11,928.3%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Crinetics Pharmaceuticals stock price performed over time

Intraday

2.33%

1 week

-0.27%

1 month

20.29%

1 year

193.05%

YTD

54.1%

QTD

22.42%

How have Crinetics Pharmaceuticals's revenue and profit performed over time

Revenue

$1.97M

Gross profit

$1.97M

Operating income

-$248.16M

Net income

-$235.46M

Gross margin

100%

Net margin

-11,928.3%

The operating margin has plunged by 196% YoY and by 127% from the previous quarter

The net margin has dropped by 192% year-on-year and by 123% since the previous quarter

CRNX's gross profit has plunged by 54% YoY and by 51% from the previous quarter

The revenue has dropped by 54% year-on-year and by 51% since the previous quarter

What is Crinetics Pharmaceuticals's growth rate over time

What is Crinetics Pharmaceuticals stock price valuation

P/E

N/A

P/B

4.36

P/S

2,007.91

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

2,015.78

The company's EPS fell by 15% YoY

CRNX's equity has surged by 62% since the previous quarter

CRNX's P/B is 28% above its 5-year quarterly average of 3.4 and 18% above its last 4 quarters average of 3.7

The P/S is 188% above the last 4 quarters average of 697.3 and 130% above the 5-year quarterly average of 873.8

The revenue has dropped by 54% year-on-year and by 51% since the previous quarter

How efficient is Crinetics Pharmaceuticals business performance

The company's return on sales has shrunk by 192% YoY and by 123% QoQ

The ROA has increased by 22% YoY and by 19% from the previous quarter

The company's return on equity rose by 20% QoQ and by 19% YoY

The return on invested capital rose by 14% year-on-year and by 9% since the previous quarter

What is CRNX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for CRNX.

How did Crinetics Pharmaceuticals financials performed over time

The total assets has surged by 54% since the previous quarter

The quick ratio has soared by 54% YoY and by 37% QoQ

The debt is 94% smaller than the equity

CRNX's equity has surged by 62% since the previous quarter

CRNX's debt to equity is down by 40% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.